Cite
Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
MLA
Wilde, Anne-Christin Beatrice, et al. “Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.” Journal of Clinical Medicine, vol. 11, no. 3, Feb. 2022, p. 681. EBSCOhost, https://doi.org/10.3390/jcm11030681.
APA
Wilde, A.-C. B., Greverath, L. M., Steinhagen, L. M., de Chamorro, N. W., Leicht, E., Fischer, J., Herta, T., Berg, T., Preuss, B., Klein, R., Tacke, F., & Müller, T. (2022). Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Journal of Clinical Medicine, 11(3), 681. https://doi.org/10.3390/jcm11030681
Chicago
Wilde, Anne-Christin Beatrice, Lena Maria Greverath, Lara Marleen Steinhagen, Nina Wald de Chamorro, Elise Leicht, Janett Fischer, Toni Herta, et al. 2022. “Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.” Journal of Clinical Medicine 11 (3): 681. doi:10.3390/jcm11030681.